Single-dose induction with daclizumab immediately after liver transplantation in pediatric patients

被引：2

作者：

Heffron, TG ^{[1
]}

Pillen, T ^{[1
]}

Smallwood, GA ^{[1
]}

Martinez, E ^{[1
]}

de Vera, ME ^{[1
]}

Romero, R ^{[1
]}

机构：

[1] Emory Univ, Div Liver Transplantat, Atlanta, GA USA

来源：

TRANSPLANTATION PROCEEDINGS | 2001年 / 33卷 / 1-2期

关键词：

D O I：

10.1016/S0041-1345(00)02548-3

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：1449 / 1449

页数：1

共 3 条

[1] The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients [J].

Eckhoff, DE ;

McGuire, B ;

Sellers, M ;

Contreras, J ;

Frenette, L ;

Young, C ;

Hudson, S ;

Bynon, JS .

TRANSPLANTATION, 2000, 69 (09) :1867-1872

[2] Experience with daclizumab in liver transplantation - Renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation [J].

Hirose, R ;

Roberts, JP ;

Quan, D ;

Osorio, RW ;

Freise, C ;

Ascher, NL ;

Stock, PG .

TRANSPLANTATION, 2000, 69 (02) :307-311

[3] Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation [J].

Vincenti, F ;

Kirkman, R ;

Light, S ;

Bumgardner, G ;

Pescovitz, M ;

Halloran, P ;

Neylan, J ;

Wilkinson, A ;

Ekberg, H ;

Gaston, R ;

Backman, L ;

Burdick, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (03) :161-165

← 1 →